Latest Articlesddd

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

July 31, 2023 0

ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen (IMGN), a leader in the …

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

July 26, 2023 0

Merck and Moderna Inc Announcement Merck (MRK) and Moderna Inc (MRNA . . . This content …

Why Syndax and Incyte Traded UP in Today’s Early Morning  

July 24, 2023 0

Syndax Pharmaceuticals and Incyte Syndax Pharmaceuticals (SNDX) and Incyte (INCY) announced positive data from the pivotal …

Halozyme Therapeutics’ Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

July 21, 2023 0

The way drugs are being delivered into patients’ bodies have become more than ever considered important …

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

July 20, 2023 0

Merck and Kintara in the NEWS Treating cancers that have no treatments should be a priority …

Treatments for Untreatable Diseases

July 16, 2023 0

Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer …

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

July 6, 2023 0

BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical (BMRN) announced that …

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra for the Treatment of Type 1 Diabetes

June 30, 2023 0

CellTrans Inc FDA Approval for Lantidra for Type 1 Diabetes The U.S. Food and Drug Administration …

The U.S. FDA Approved BioMarin Pharmaceutical’s ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

June 30, 2023 0

BioMarin Pharmaceutical US FDA Approved ROCTAVIAN BioMarin Pharmaceutical (BMRN) announced that the U.S. FDA approved ROCTAVIAN …

Bayer & BlueRock Therapeutics: A First Neuronal Stem Cell Therapy to Show Positive Results in Phase I Clinical Study for Parkinson’s Disease    

June 29, 2023 0

Bayer and BlueRock Therapeutics Berlin, Germany and Cambridge, M.A., U.S.A., June 28, 2023 – Bayer AG (BAYRY) …

Prohost Letter #455

June 28, 2023 0

Prohost Letter #455 Introduction Our Prohost Letter disappeared for six months. Several reasons dictated our decision …

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in Netherlands to Start Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca Imfinzi for Treatment of Pancreatic Cancer

June 27, 2023 0

AIM ImmunoTech Announcement AIM ImmunoTech (AIM) - an immuno-pharma company focused on the research and development …

Celmatix Inc: Revolutionizing Fertility Treatments

June 27, 2023 0

Celmatix Inc. Celmatix Inc., announced the identification of promising early leads in its latest drug program, …

Arbutus Biopharma Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial That Includes a PD-1 Monoclonal Antibody Nivolumab

June 21, 2023 0

Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma (ABUS) announced that the first patient has …

Vera Therapeutics Announces Positive Week 36 Safety and Efficacy Results in Phase 2b Clinical Trial of Atacicept in IgA Nephropathy

June 20, 2023 0

Vera Therapeutics Vera Therapeutics (VERA) announced that Phase 2b ORIGIN clinical trial of atacicept for IgA …

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

June 14, 2023 0

Today at 2.30... Today at 2.30, the Federal Reserve Chairman Jerome Powell will speak to the …

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

June 1, 2023 0

UT Southwestern Medical Center and RenovoRx RenovoRx Inc (RNXT) announced that the University of Texas (UT) …

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

May 30, 2023 0

Amylyx Pharmaceuticals  Amylyx Pharmaceuticals (AMLX) announced an update on the ongoing review of its Marketing Authorization …

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

May 26, 2023 0

Inside the Revolution In the Treatments of Untreatable Diseases We are now living a great revolution …

Our Eyes Are on Reata Pharmaceuticals Today

May 25, 2023 0

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease …